Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
We have previously shown that absence of the mouse mdr1a (also called mdr3) P-glycoprotein in mdr1a (-/-) "knockout" mice has a profound effect on the tissue distribution and elimination of vinblastine and ivermectin, and hence on the toxicity of these compounds. We show here that the mouse mdr1a and the human MDR1 P-glycoprotein actively transport ivermectin, dexamethasone, digoxin, and cyclosporin A and, to a lesser extent, morphine across a polarized kidney epithelial cell layer in vitro. Injection of these radio-labeled drugs in mdr1a (-/-) and wild-type mice resulted in markedly (20- to 50-fold) higher levels of radioactivity in mdr1a (-/-) brain for digoxin and cyclosporin A, with more moderate effects for dexamethasone (2- to 3-fold) and morphine (1.7-fold). Digoxin and cyclosporin A were also more slowly eliminated from mdr1a (-/-) mice. Our findings show that P-glycoprotein can be a major determinant for the pharmacology of several medically important drugs other than anti-cancer agents, especially in the blood-brain barrier. These results may explain a range of pharmacological interactions observed between various drugs in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
The Pharmacological Basis of Therapeutics
(1976) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/33.4.373a · Cited by 8,209
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Self-citationTHE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE
Endicott, J. A., & Ling, V. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.001033 · Cited by 2,071
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1981) · PubMed · Cited by 1,459
Cited by
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
“Mdr1, also called P-glycoprotein, has been widely studied in this context, and knockout mice show an increase in a wide variety of small lipophilic drugs entering the brain, as well as endogenous molecules (Schinkel et al. 1994, 1995, 1996).”
BackgroundBrain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
“Mutant mice with a genetic disruption of the mdr1a gene show increased accumulation of [(3)H]dexamethasone in the brain (90).”
BackgroundBrain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
The Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Self-citationCalcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Self-citationSchinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Self-citationKim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1269 · Cited by 1,054
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Self-citationNeuroendocrine Regulation of Immunity
Webster, J. I., Tonelli, L., & Sternberg, E. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.082401.104914 · Cited by 957
Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4028 · Cited by 937
Self-citationThe role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
The superfamily of organic anion transporting polypeptides
Hagenbuch, B., & Meier, P. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00633-8 · Cited by 861
van Helvoort, A., Smith, A. J., Sprong, H., Fritzsche, I., Schinkel, A. H., Borst, P., & van Meer, G. (1996) · Cell · doi:10.1016/s0092-8674(00)81370-7 · Cited by 855
Self-citationThe blood–brain barrier in health and disease
Daneman, R. (2012) · Annals of Neurology · doi:10.1002/ana.23648 · Cited by 754
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Self-citationHolsboer, F. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(98)90056-5 · Cited by 654
Acute heart transplant rejection due to Saint John's wort
Ruschitzka, F., Meier, P. J., Turina, M., Lüscher, T. F., & Noll, G. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05467-7 · Cited by 644
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Drug Transfer and Metabolism by the Human Placenta
Syme, M. R., Paxton, J. W., & Keelan, J. A. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443080-00001 · Cited by 634
Herb-Drug Interactions: A Literature Review
Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H. L., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 633
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Evers, R., Kool, M., van Deemter, L., Janssen, H., Calafat, J., Oomen, L. C., Paulusma, C. C., Oude Elferink, R. P., Baas, F., Schinkel, A. H., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119886 · Cited by 620
Self-citationRole of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Importance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J. R., & Raevsky, O. A. (1998) · Journal of Drug Targeting · doi:10.3109/10611869808997889 · Cited by 587
JOHNE, A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101944 · Cited by 586
Opioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations
Chu, L. F., Angst, M. S., & Clark, D. (2008) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31816b2f43 · Cited by 575
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Panwala, C. M., Jones, J. C., & Viney, J. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.10.5733 · Cited by 567
P-glycoprotein and multidrug resistance
Gottesman, M. M., Pastan, I., & Ambudkar, S. V. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80091-8 · Cited by 560
Decreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs
Hackstein, H., & Thomson, A. W. (2004) · Nature Reviews Immunology · doi:10.1038/nri1256 · Cited by 545
Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations
Lee, G., Dallas, S., Hong, M., & Bendayan, R. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01513-8 · Cited by 539
Multidrug resistance: molecular mechanisms and clinical relevance
Ling, V. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051053 · Cited by 522
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom, A., Cox, M. C., Acharya, M. R., & Figg, W. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.182 · Cited by 473
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
Pardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9324-2 · Cited by 447
The Blood-Brain Barrier in Neuroinflammatory Diseases
de Vries, H. E., Kuiper, J., de Boer, A. G., Van Berkel, T. J. C., & Breimer, D. D. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01320-6 · Cited by 429
Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Wacher, V. J., Silverman, J. A., Zhang, Y., & Benet, L. Z. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980082d · Cited by 423
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A., & Morgan, P. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 421
P-glycoprotein—A mediator of multidrug resistance in tumour cells
Germann, U. A. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00057-3 · Cited by 405
Fromm, M. F., Kim, R. B., Stein, C. M., Wilkinson, G. R., & Roden, D. M. (1999) · Circulation · doi:10.1161/01.cir.99.4.552 · Cited by 402
Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain
Noé, B., Hagenbuch, B., Stieger, B., & Meier, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10346 · Cited by 396
Huang, S., Strong, J. M., Zhang, L., Reynolds, K. S., Nallani, S., Temple, R., Abraham, S., Habet, S. A., Baweja, R. K., Burckart, G. J., et al. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007312153 · Cited by 396
Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer
Morgan, E. T., Goralski, K. B., Piquette-Miller, M., Renton, K. W., Robertson, G. R., Chaluvadi, M. R., Charles, K. A., Clarke, S. J., Kacevska, M., Liddle, C., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018747 · Cited by 395
The Blood–Brain Barrier and Epilepsy
Oby, E., & Janigro, D. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00817.x · Cited by 388
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
The Molecular Constituents of the Blood–Brain Barrier
Chow, B. W., & Gu, C. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.003 · Cited by 380
Meijer, O. C. (1998) · Endocrinology · doi:10.1210/en.139.4.1789 · Cited by 375
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 374
Transporter-Mediated Permeation of Drugs Across the Blood–Brain Barrier
Tamai, I., & Tsuji, A. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200011)89:11<1371::aid-jps1>3.0.co;2-d · Cited by 363
Expression and function of efflux drug transporters in the intestine
Takano, M., Yumoto, R., & Murakami, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.005 · Cited by 356
Glucocorticoids are critical regulators of dendritic spine development and plasticity in vivo
Liston, C., & Gan, W.-B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110444108 · Cited by 352
Smit, J. W., Huisman, M. T., van Tellingen, O., Wiltshire, H. R., & Schinkel, A. H. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7963 · Cited by 352
Self-citationIs the Role of the Small Intestine in First-Pass Metabolism Overemphasized?
Lin, J. H., Chiba, M., & Baillie, T. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01402-9 · Cited by 352
de Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy
Silva, R., Vilas-Boas, V., Carmo, H., Dinis-Oliveira, R. J., Carvalho, F., de Lourdes Bastos, M., & Remião, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.013 · Cited by 339
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function
Fung, K. L., & Gottesman, M. M. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.02.014 · Cited by 335
Pardridge, W. M. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199707000-00001 · Cited by 328
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Breedveld, P., Beijnen, J. H., & Schellens, J. H. M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.009 · Cited by 323
Poller, B., Gutmann, H., Krähenbühl, S., Weksler, B., Romero, I., Couraud, P., Tuffin, G., Drewe, J., & Huwyler, J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05730.x · Cited by 317
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Several major antiepileptic drugs are substrates for human P-glycoprotein
Luna-Tortós, C., Fedrowitz, M., & Löscher, W. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.032 · Cited by 310
Drug–drug interaction mediated by inhibition and induction of P-glycoprotein
Lin, J. H. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00171-0 · Cited by 309
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Drug efflux transporters in the CNS
Sun, H., Dai, H., Shaik, N., & Elmquist, W. F. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00172-2 · Cited by 304
Gao, B., Stieger, B., Noé, B., Fritschy, J.-M., & Meier, P. J. (1999) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549904701005 · Cited by 304
Molecular aspects of hepatobiliary transport
Muller, M., & Jansen, P. L. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.272.6.g1285 · Cited by 299
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299
Inhibition of P-Glycoprotein by Newer Antidepressants
Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046532 · Cited by 292
Farrell, R. J., Murphy, A., Long, A., Donnelly, S., Cherikuri, A., O'Toole, D., Mahmud, N., Keeling, P. W. N., Weir, D. G., & Kelleher, D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70210-1 · Cited by 291
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4
Cummins, C. L., Jacobsen, W., & Benet, L. Z. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1036 · Cited by 289
van Oers, H. J. J., de Kloet, E. R., Whelan, T., & Levine, S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-10171.1998 · Cited by 285
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K. F., van Asperen, J., Borst, P., & Schinkel, A. H. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15775.x · Cited by 282
Self-citationSt John's Wort increases expression of P‐glycoprotein: Implications for drug interactions
Hennessy, M., Kelleher, D., Spiers, J. P., Barry, M., Kavanagh, P., Back, D., Mulcahy, F., & Feely, J. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01516.x · Cited by 280
Karssen, A. M. (2001) · Endocrinology · doi:10.1210/en.142.6.2686 · Cited by 280
Pavek, P., Merino, G., Wagenaar, E., Bolscher, E., Novotna, M., Jonker, J. W., & Schinkel, A. H. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073916 · Cited by 278
Self-citationModulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051055 · Cited by 277
Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Morris, M. E., & Zhang, S. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.003 · Cited by 273
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
Self-citationIssues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Distribution in Tissue
Müller, M., dela Peña, A., & Derendorf, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1441-1453.2004 · Cited by 268
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Self-citation
Metadata
- Authors
- Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-10-01
- Volume
- 96
- Issue
- 4
- Pages
- 1698-1705
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136564762
- Cited by
- 1,107
- References
- 42
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.